Albumin‑bilirubin Grade is an Independent Prognostic Factor for Small Lung Cell Cancer

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2024 Jan 12

PMID 38213660

Authors

Shicheng Liu

Qingtao Zhao

Zengming Wang

Bin Zhao

Xiaopeng Zhang

Affiliations

Soon will be listed here.

Abstract

Albumin-bilirubin (ALBI) grade was first described in 2015 as an indicator of liver dysfunction in patients with hepatocellular carcinoma. ALBI grade has been reported to have prognostic value in several malignancies including non-small cell lung cancer (NSCLC). The present study aimed to explore the prognostic impact of ALBI grade in patients with small cell lung cancer (SCLC). It retrospectively analyzed 135 patients with SCLC treated at Hebei General Hospital between April 2015 and August 2021. Patients were divided into two groups according to the cutoff point of ALBI grade determined by the receiver operating characteristic (ROC) curve: Group 1 with pre-treatment ALBI grade ≤-2.55 for an improved hepatic reserve and group 2 with ALBI grade >-2.55. Kaplan-Meier and Cox regression analysis were performed to assess the potential prognostic factors associated with progression free survival (PFS) and overall survival (OS). Propensity score matching (PSM) was applied to eliminate the influence of confounding factors. PFS and OS (P<0.001) were significantly improved in group 1 compared with in group 2. Multivariate analysis revealed that sex (P=0.024), surgery (P=0.050), lactate dehydrogenase (LDH; P=0.038), chemotherapy (P=0.038) and ALBI grade (P=0.028) are independent risk factors for PFS and that surgery (P=0.013), LDH (P=0.039), chemotherapy (P=0.009) and ALBI grade (P=0.013) are independent risk factors for OS. After PSM, ALBI grade is an independent prognostic factor of PFS (P=0.039) and OS (P=0.007). It was concluded that ALBI grade was an independent prognostic factor in SCLC.

Citing Articles

Prognostic value of albumin-bilirubin grade in lung cancer: a meta-analysis.

Jiang J, Li H, Chen L, Qiu X J Cardiothorac Surg. 2024; 19(1):685.

PMID: 39734193 PMC: 11684295. DOI: 10.1186/s13019-024-03311-8.

References

Thompson D, Perry L, Renouf J, Vodanovich D, Hong Lee A, Dimiri J . Prognostic utility of inflammation-based biomarkers, neutrophil-lymphocyte ratio and change in neutrophil-lymphocyte ratio, in surgically resected lung cancers. Ann Thorac Med. 2021; 16(2):148-155. PMC: 8109682. DOI: 10.4103/atm.ATM_382_20. View

Harimoto N, Yoshizumi T, Sakata K, Nagatsu A, Motomura T, Itoh S . Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. World J Surg. 2017; 41(11):2805-2812. DOI: 10.1007/s00268-017-4097-1. View

Fearon K, Strasser F, Anker S, Bosaeus I, Bruera E, Fainsinger R . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489-95. DOI: 10.1016/S1470-2045(10)70218-7. View

Ikeda S, Yoshioka H, Ikeo S, Morita M, Sone N, Niwa T . Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status. BMC Cancer. 2017; 17(1):797. PMC: 5704395. DOI: 10.1186/s12885-017-3814-3. View

Lee S, Song M, Kim S, Park M . Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study. PLoS One. 2019; 14(5):e0216173. PMC: 6497276. DOI: 10.1371/journal.pone.0216173. View

Zhan W, Liu Y, Gao Y, Gong R, Wang W, Zhang R . RMI2 plays crucial roles in growth and metastasis of lung cancer. Signal Transduct Target Ther. 2020; 5(1):188. PMC: 7471275. DOI: 10.1038/s41392-020-00295-4. View

Wang D, Guo D, Shi F, Zhu Y, Li A, Kong L . The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancer. Future Oncol. 2019; 15(29):3367-3379. DOI: 10.2217/fon-2019-0288. View

Racanelli V, Rehermann B . The liver as an immunological organ. Hepatology. 2006; 43(2 Suppl 1):S54-62. DOI: 10.1002/hep.21060. View

Tewari N, Martin-Ucar A, Black E, Beggs L, Beggs F, Duffy J . Nutritional status affects long term survival after lobectomy for lung cancer. Lung Cancer. 2007; 57(3):389-94. DOI: 10.1016/j.lungcan.2007.03.017. View

10.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

11.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

12.

Kragh-Hansen U, Chuang V, Otagiri M . Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull. 2002; 25(6):695-704. DOI: 10.1248/bpb.25.695. View

13.

Robinson M, Harmon C, OFarrelly C . Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016; 13(3):267-76. PMC: 4856809. DOI: 10.1038/cmi.2016.3. View

14.

Tsilimigras D, Hyer J, Moris D, Sahara K, Bagante F, Guglielmi A . Prognostic utility of albumin-bilirubin grade for short- and long-term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multi-institutional analysis of 706 patients. J Surg Oncol. 2019; 120(2):206-213. DOI: 10.1002/jso.25486. View

15.

Otagiri M . A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet. 2005; 20(5):309-23. DOI: 10.2133/dmpk.20.309. View

16.

Jin Y, Zhao L, Peng F . Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer. Clinics (Sao Paulo). 2013; 68(5):686-93. PMC: 3654299. DOI: 10.6061/clinics/2013(05)17. View

17.

Ito S, Ito H, Sato N, Hirayama Y, Kusakabe T, Terui T . Clinical factors associated with the therapeutic outcome of chemotherapy in very elderly cancer patients. Int J Clin Oncol. 2019; 24(5):596-601. PMC: 6469648. DOI: 10.1007/s10147-018-01385-8. View

18.

Nakagawa T, Toyazaki T, Chiba N, Ueda Y, Gotoh M . Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery. Interact Cardiovasc Thorac Surg. 2016; 23(4):560-6. DOI: 10.1093/icvts/ivw175. View

19.

van Meerbeeck J, Fennell D, De Ruysscher D . Small-cell lung cancer. Lancet. 2011; 378(9804):1741-55. DOI: 10.1016/S0140-6736(11)60165-7. View

20.

Hsieh A, Tahkar H, Koczwara B, Kichenadasse G, Beckmann K, Karapetis C . Pre-treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer. Asia Pac J Clin Oncol. 2017; 14(2):e64-e70. DOI: 10.1111/ajco.12674. View